Biopharmaceutical company Corstasis Therapeutics Inc on Thursday announced a strategic collaboration with U.S. Heart and Vascular, a cardiovascular management services platform, to integrate ENBUMYST (bumetanide nasal spray) into outpatient heart failure care.

The partners will co-develop value-based care pathways for fluid overload management in patients with congestive heart failure, liver disease, and chronic kidney disease. Initiatives include validating clinical protocols, implementing provider and staff training, and capturing outcomes and economic data to support future reimbursement strategies.

ENBUMYST has received FDA approval for treating oedema associated with congestive heart failure, hepatic disease, and renal disease, including nephrotic syndrome in adults.

The collaboration aims to enable earlier intervention, reduce readmissions, improve fluid management, and enhance cost-effective outpatient care. By targeting fluid overload, the initiative addresses a major contributor to hospitalisations and repeat admissions.